Has the French Biotech Industry valuation changed over the past few years?

Investors are optimistic on the French Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 8.8x is lower than the industry's current PS ratio of 21.6x.

Which industries have driven the changes within the French Healthcare industry?

There are no additional sub-industries under this industry.

French (CAC) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 22 Sep 2026	€10.5b	€483.3m	-€903,347,835.52	16.5x	-11.6x	21.6x
Thu, 20 Aug 2026	€11.8b	€482.2m	-€900,752,325.70	16.5x	-13.1x	24.5x
Sat, 18 Jul 2026	€12.9b	€506.8m	-€887,388,264.29	19.4x	-14.5x	25.4x
Mon, 15 Jun 2026	€9.4b	€495.2m	-€860,613,195.80	18.6x	-10.9x	18.9x
Wed, 13 May 2026	€11.3b	€518.0m	-€834,999,411.84	16.2x	-13.5x	21.8x
Fri, 10 Apr 2026	€11.1b	€502.1m	-€819,269,161.82	13.5x	-13.6x	22.1x
Sun, 08 Mar 2026	€10.8b	€560.8m	-€765,563,518.53	13x	-14.1x	19.2x
Tue, 03 Feb 2026	€10.6b	€559.7m	-€763,436,394.32	14.3x	-13.9x	19x
Thu, 01 Jan 2026	€12.1b	€641.5m	-€693,945,582.75	9.8x	-17.5x	18.9x
Sat, 29 Nov 2025	€2.6b	€637.1m	-€431,361,348.64	10.6x	-6x	4.1x
Mon, 27 Oct 2025	€2.5b	€637.2m	-€407,294,787.85	10.1x	-6.1x	3.9x
Wed, 24 Sep 2025	€2.3b	€635.9m	-€451,722,432.41	12.9x	-5.2x	3.7x
Fri, 22 Aug 2025	€2.6b	€674.3m	-€446,545,663.08	15.4x	-5.8x	3.9x
Sun, 20 Jul 2025	€2.0b	€656.2m	-€453,401,230.40	15.7x	-4.4x	3x
Tue, 17 Jun 2025	€2.0b	€666.9m	-€495,948,575.22	17.5x	-4.1x	3x
Thu, 15 May 2025	€2.5b	€671.7m	-€678,883,056.33	39.4x	-3.6x	3.7x
Sat, 12 Apr 2025	€2.1b	€650.7m	-€549,092,612.16	14.2x	-3.9x	3.3x
Mon, 10 Mar 2025	€2.5b	€651.9m	-€521,155,581.40	16.6x	-4.7x	3.8x
Wed, 05 Feb 2025	€2.3b	€650.2m	-€527,164,521.22	16.7x	-4.4x	3.6x
Fri, 03 Jan 2025	€2.4b	€650.9m	-€529,496,316.44	18.2x	-4.6x	3.7x
Sun, 01 Dec 2024	€2.4b	€654.0m	-€547,103,426.84	18.5x	-4.4x	3.7x
Tue, 29 Oct 2024	€2.8b	€641.3m	-€519,366,537.20	18.7x	-5.4x	4.4x
Thu, 26 Sep 2024	€3.0b	€545.5m	-€591,076,284.04	27.7x	-5x	5.4x
Sat, 24 Aug 2024	€3.1b	€520.1m	-€578,507,082.20	37.5x	-5.4x	6x
Mon, 22 Jul 2024	€2.9b	€511.7m	-€566,393,417.73	28.9x	-5.1x	5.7x
Wed, 19 Jun 2024	€3.0b	€514.3m	-€569,042,890.41	26.7x	-5.3x	5.8x
Fri, 17 May 2024	€3.3b	€502.3m	-€592,426,100.94	27.9x	-5.6x	6.6x
Sun, 14 Apr 2024	€3.3b	€515.7m	-€629,475,775.73	28.4x	-5.2x	6.3x
Tue, 12 Mar 2024	€3.1b	€567.7m	-€646,706,019.23	21.4x	-4.8x	5.5x
Thu, 08 Feb 2024	€3.0b	€558.9m	-€675,004,465.79	21.7x	-4.4x	5.4x
Sat, 06 Jan 2024	€3.2b	€594.2m	-€683,028,253.00	23.1x	-4.7x	5.4x
Mon, 04 Dec 2023	€3.2b	€594.5m	-€684,435,706.00	21.8x	-4.6x	5.3x
Wed, 01 Nov 2023	€3.1b	€803.4m	-€567,060,758.00	21.4x	-5.5x	3.9x
Fri, 29 Sep 2023	€3.5b	€861.6m	-€629,774,671.00	14.4x	-5.6x	4.1x


FR Market	-1.30%
Healthcare	-2.15%
Biotech	-8.04%
Biotech	-8.04%

Company	Last Price	7D	1Y	Valuation
ALERS Eurobio Scientific Société anonyme	€25.10	23.0% +€47.3m	-1.6%	PE51.9x
ABNX ABIONYX Pharma	€1.87	10.4% +€7.5m	-51.7%	PS19.4x
ALTME TME Pharma	€0.11	11.3% +€1.1m	13.4%	PE-3.2x
ADOC Adocia	€3.58	1.0% +€704.4k	-57.3%	PS18.2x
ALCOX Nicox	€0.34	1.9% +€572.8k	-8.8%	PS1.8x

Announcement • Sep 15

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company And Advances .HEAL-101 And .HEAL-201 Programs

Cellectis announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases. The Company’s strategic transformation builds on the achievement of promising preclinical proof-of-concept for its lead candidate programs, .HEAL-101 and .HEAL-201. .HEAL-101 is an in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia and .HEAL-201 is an in vivo epigenetic editing product candidate targeting PCSK9 for severe hypercholesterolemia. Severe hypertriglyceridemia (sHTG) remains a significant unmet medical need, with affected patients facing a high risk of acute pancreatitis, an increased burden of cardiovascular disease, and limited treatment options. .HEAL-101 is being developed for patients with high-risk sHTG, including those with triglyceride levels =880 mg/dL or =500 mg/dL with a history of acute pancreatitis, representing an estimated target population of approximately 1 to 2 million patients across the United States and Europe. .HEAL-101 targets the human APOC3 gene, a well-validated target for sHTG, via a TALE-base editor specific to the APOC3 gene (“APOC3 TALEB”) formulated in Lipid Nanoparticles (LNP). The APOC3 TALEB displayed high on-site base editing activity when transfected as mRNA in a hepatic cell line (mean base editing >70%) and base editing translated into a deep and significant reduction of APOC3 protein secretion (mean reduction >70%). APOC3 TALEB displayed a highly specific base editing profile using an unbiased, genome wide off-site identification method. Intravenous injection of .HEAL-101 in a liver humanized normolipidemic murine model successfully edited human APOC3 (mean on-site base editing ~55%) and decreased plasmatic APOC3 levels (mean decrease ~60%; up to 70%), associated with a decrease of circulating triglycerides (mean decrease ~45%; up to 68% with respect to pre-treatment baseline). It did not significantly increase the level of liver ALT (alanine aminotransferase) compared to untreated control. Intravenous injection of .HEAL-101 in a hypertriglyceridemic humanized APOC3 transgenic murine model significantly decreased plasmatic APOC3 levels (mean decrease ~70%) and triglyceride levels (means decrease ~76%) compared to pre-treatment baseline, demonstrating the efficacy of .HEAL-101 in a relevant disease model. The Company plans to initiate a Phase 1 investigator-initiated trial (IIT) in China and share the preliminary clinical data from this program in H2 2027. Severe hypercholesterolemia remains a major driver of atherosclerotic cardiovascular disease, with many high-risk patients continuing to experience elevated low-density lipoprotein cholesterol (LDL-C) levels despite currently available therapies. This burden is particularly significant among younger high-risk patients with severe genetic forms of hypercholesterolemia and those with premature cardiovascular disease, representing an estimated 1 to 2 million patients across the United States and Europe. .HEAL-201 is being developed to address the needs of these high-risk patient populations. .HEAL-201 targets the human PCSK9 gene, a well-validated target for severe hypercholesterolemia, via a TALE-epigenetic modulator specific to the promoter of PCSK9 (“PCSK9 TALEM”) formulated in LNP to treat severe hypercholesterolemia. The PCSK9 TALEM displayed a high on-site epigenome editing activity when transfected as mRNA in a hepatic cell line (mean base editing >90%). Epigenome editing translates into a stable, deep and significant reduction of PCSK9 transcript levels and PCSK9 secretion without evidence for off-site gene and protein modulation. Intravenous injection of PCSK9 TALEM mRNA LNPs in a liver humanized murine model, successfully decreased plasmatic levels of PCSK9 (mean >90%). The Company plans to initiate a Phase 1 IIT in China and share the preliminary clinical data from this program in H1 2028. Cellectis’ core competencies encompass nuclease editing, base editing, epigenetic editing and transcriptional regulation. While most gene editing companies focus on a single editing modality, Cellectis’ broad gene editing toolbox built over a quarter century allows for a combination of therapeutic targets utilizing several gene editing modalities. In 2026, despite continued conviction in the promise of allogeneic CAR T-cell therapies and strong physician interest in lasme-cel and eti-cel, the commercial and clinical landscape for B-ALL and NHL changed materially. Continued and recently accelerated advances in frontline treatment regimens have lowered relapse rates, reducing the number of patients progressing to later lines of therapy. Concurrently, the rapid emergence of bispecific antibodies and in vivo CAR-T approaches has intensified competition in second and third-line treatment settings. Together, these dynamics have reduced the addressable patient population for lasme-cel and eti-cel, resulting in slower enrollment, a potentially longer and more costly development pathway, and therefore a delayed timeline to potential registration. After a thorough assessment of the evolving therapeutic landscape and strategic review, the Company has determined that the most effective use of its financial and operational resources is to focus on and accelerate the advancement of its most promising in vivo gene editing assets. Cellectis will therefore exit the development of lasme-cel and eti-cel, while seeking strategic partnering opportunities to maximize their value. The Company will realign its organization and resources to focus on its in vivo Gene Editing pipeline and support its existing cell therapy partnerships with AstraZeneca, Allogene, Servier and Iovance. These combined actions are being designed to extend the Company's cash runway into H2 2028, providing financial flexibility to advance Cellectis’ in vivo Gene Editing pipeline through key development milestones.

French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New major risk - Share price stability

MaaT Pharma Provides Update On MaaT013 (Xervyteg) Development Plan Following CHMP Negative Opinion

Sensorion Announces Registration And Connection Details For SENS-601 Program Day And Provides Updates On SENS-601 And SENS-401 Product Pipeline

New major risk - Market cap size

New minor risk - Share price stability

Adocia Presents Data On AdoShell Platform Scalability And BioChaperone Lispro Phase 3 Results

Price target decreased by 8.5% to €9.83

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company And Advances .HEAL-101 And .HEAL-201 Programs

Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China

Inventiva Presents Multiple Abstracts on Lanifibranor At Paris MASH 2026

New minor risk - Shareholder dilution

New minor risk - Share price stability

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

GENFIT Reports Positive Phase 1B Data for GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

genOway Société anonyme, Annual General Meeting, Jun 26, 2026

New minor risk - Financial data availability